Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.
A study has found that there is a dose-dependent relationship between increased risk for depression and cardiometabolic diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback